Figure 7. STING agonist enhances the efficacy of an OVA-targeted peripheral vaccine.

(A) Mice bearing Quad-GL261 glioma in the brain received with control solvent (N=10, closed circle), OVA peptide vaccination alone (N=10, closed triangle), c-di-GMP alone (N=10, open circle), or c-di-GMP with OVA peptide vaccination (N=10, open triangle) on day 14 following tumor inoculation. Survival was monitored. *p < 0.05, **p < 0.01 based on Log-rank test. (B) CD8⁺ BILs were enumerated for each group by flow cytometry (5 mice/group). *p < 0.05 based on ANOVA test. (C) Cytotoxic activity of freshly isolated BILs against the vaccine-targeted OVA epitope was evaluated by ⁵¹Cr-release assay using control GL261 (gray bars) or OVA_257-264 peptide-pulsed GL261 cells (black bars) as target cells at E/T ratio 10 : 1 (5 mice/group). Each experiment was performed at least twice. *p < 0.05 based on ANOVA test. **p < 0.05 based on Student’s t-test.